The ANPA condemns injustice and deplores the pernicious impact of systematic racism on the patients we serve. Since its inception over 30 years ago the ANPA and, most especially the patients served, have benefited from the diversity of its membership - the ANPA has members spanning the globe committed to the wellbeing of all communities.   Our mission of improving the lives of people with neuropsychiatric disorders allows ANPA to address the societal inequities that are barriers to good health and well-being.  We stand with those who express outrage over institutionalized racism and police brutality, and add our voice to the demand for social justice for all people, now.  The ANPA is committed to caring for the mental and physical health of all people regardless of race, religion, gender or nationality.  

ABOUT ANPA

The American Neuropsychiatric Association (ANPA) is a non-profit organization of professionals in behavioral neurology, neuropsychiatry, neuropsychology, and the clinical neurosciences. Established in 1988, ANPA has grown to over 500 members from around the world. ANPA's mission is to improve the lives of people with disorders at the interface of psychiatry and neurology.


MISSION

To improve the lives of people with disorders at the interface of psychiatry and neurology

VISION

ANPA will transform recognition, understanding and treatment of all neuropsychiatric disorders

WELCOME FROM THE PRESIDENT

  KALOYAN TANEV, MD, FANPA

Welcome to the American Neuropsychiatric Association’s (ANPA) website and to our community. ANPA’s vision is to be the professional home for clinicians, academicians, and researchers in neuropsychiatry, behavioral neurology, and behavioral neuroscience. Our core values include working together in a collegial and interdisciplinary fashion to provide a forum for learning, advancing knowledge of brain-behavior relations, and promoting excellent, scientific, and compassionate patient care. Annually, we produce a scientific meeting that provides high-value educational and networking opportunities to our attendees. The meeting focuses on the neuroscience of brain-behavioral relationships, and applying this knowledge to patient care. The meeting provides updates on the latest scientific breakthroughs in the conditions most commonly treated in neuropsychiatry/behavioral neurology, “hands-on” workshops for clinical examinations,  continuing medical education (CME), and maintenance of  certification (MOC) credits. In addition to the annual meeting, the ANPA supports the Journal of Neuropsychiatry and Clinical Neurosciences (JNCN), our home scientific publication.

Brief history of BNNP certification:

We live in historic times. In the late 18th-19th century, physicians identified as neurologists or psychiatrists based on their practice nature and location, not based on the mind-brain dichotomy. In the 20th century, US psychiatry diverged from both medicine and neurology based on the wide spread of psychoanalysis. However, the development of medical sciences in the 20th century, the development of psychopharmacology in the 1950s and 1960s, and the growth of neurosciences in the 1980s and 1990s laid the foundation for reunification of the parts of neurology and psychiatry that deal with brain-behavioral relationships. In the early 2000’s, the ANPA and the Society of Cognitive and Behavioral Neurology recognized this need for reunification and collaboratively applied for accreditation of a new neurological subspecialty, Behavioral Neurology and Neuropsychiatry (BNNP), to the United Council of Neurologic Subspecialties (UCNS). The UCNS approved the application in 2004. Since then, practitioners obtain BNNP subspecialty certification through qualifying examinations, and BNNP fellowship programs have established unified training curricula. The BNNP subspecialty certification identifies practitioners possessing specific competencies to treat cognitive, emotional, and behavioral disturbances related to brain dysfunction.

The ANPA membership:

The ANPA membership comprises clinicians, educators, scientists, and members in training from several related areas – neuropsychiatry, behavioral neurology, neuroimaging, psychology, neuropsychology, neuroanatomy, basic neuroscience, rehabilitation, and allied health.

The ANPA is the village of BNNP practitioners, educators, and researchers.

The ANPA annual meeting is a high-quality, high-impact educational event. When I return from a meeting, I feel inspired by symposia that show new views through the kaleidoscope of brain anatomy, physiology, pathology, behavior, and symptoms.

The ANPA annual meeting is also a great networking opportunity. As a new member, I was amazed to be able to speak face-to-face with people who were editors of landmark textbooks in neuropsychiatry and behavioral neurology. Over the years, I have benefited from the mentorship of many ANPA members, have enjoyed getting to know BNNP colleagues, and have become friends with many.

Through its journal, publications of systematic reviews and expert opinions, and through the UCNS Certification Exam, the ANPA has established itself as The Organization setting the standards of neuropsychiatric care. Rightfully so. I believe that ANPA is one of the hidden gems in medicine. Although relatively small – about 1,000 members, it is influential on a national level. It feels like many more people should be interested in the work of our organization. Many physicians from neighboring specialties can benefit from ANPA’s programs and network.

My commitment to you for the next 2 years:

I will support the ANPA as a professional home to its members. ANPA has always offered high-quality educational programs and has been a professional network.

I will support growing membership involvement in the organization. Many members would like to contribute their energy and ideas to ANPA. Increasing member involvement would benefit ANPA, would widen the opportunity for members’ professional growth through participation, and would increase the organization’s network value.

I will reach out to organizations in neighboring fields to establish collaborations and to spread the word about ANPA’s value to their members. I will collaborate with the Executive and Membership Committees to create appropriate incentives to grow the membership of ANPA and expand our organization’s national and international influence.

I will collaborate with others to spread the message and excitement about neuropsychiatry and applied neurosciences to the next generation of clinicians-neuroscientists.

Please reach out to me with questions and ideas.


ANPA Officers

Kaloyan Tanev, MD, FANPA - President (2021 - 2023)

Massachusetts General Hospital

Boston, MA 

Robin Hurley, MD, FANPA - IMMEDIATE PAST PRESIDENT (2021 - 2023)
VA Medical Center, Salisbury NC

Wake Forest University School of Medicine

David Arciniegas, MD, FANPA - President Elect (2021 - 2023)

University of New Mexico School of Medicine

Clinical Professor of Neurology and Psychiatry

University of Colorado School of Medicine

Editor, Journal of Neuropsychiatry and Clinical Neurosciences

C. Edward Coffey, MD, FANPA - TREASURER (1997 - Present)

Medical University of South Carolina


ANPA Council Members


2018 - 2021

W. Curt LaFrance, Jr., MD, FANPA

Jonathan Silver, MD., FANPA


2019 - 2022

Gaston Baslet, MD, FANPA

Colin Harrington, MD, FANPA


2021 - 2024

John Campbell, MD, FANPA

Jay Salpekar, MD, FANPA

View a list of past councilors


ANPA Committee on Research

Founded in 1993, the American Neuropsychiatric Association Committee on Research (ANPA CoR) is the branch of ANPA aiming to move forward scientific and clinical knowledge in Neuropsychiatry. The committee is composed of clinician-scientists in Neuropsychiatry, Behavioral Neurology and Neuropsychology from the USA, Canada, Europe and South America. Through the ANPA’s official journal, The Journal of Neuropsychiatry and Clinical Neurosciences, the ANPA CoR has published numerous seminal systematic reviews on key neuropsychiatric topics. The committee is currently working on projects to identify best clinical practices for disorders at the frontier of Psychiatry and Neurology, in addition to establishing research priorities for future research in Neuropsychiatry.


ANPA CoR Chair

   

Dr. Simon Ducharme MD MSc

Montreal Neurological Institute

McGill University

Montreal, Canada

https://www.mcgill.ca/neuro/simon-ducharme-md-msc-frcpc

ANPA CoR Deputy Chair

Prof. Dr.med  Selma Aybek, MD

Neurology Department, Bern University Hospital

Bern University,

Bern, Switzerland

https://www.neuroscience.unibe.ch/research/personen/prof_dr_med_aybek_selma


Committee Members

Sepideh Bajestan (Stanford University)

Gaston Baslet (Harvard University)

Kevin Black (Washington University)

Joan Camprodon (Harvard University)

Andrea Cavanna (University of Birmingham)

Leandro da Costa Lane Valiengo (University of Sao Paulo)

Alan Fund (University of Toronto)

Omar Ghaffar (University of Toronto)

Curt LaFrance (Brown University)

Mia Minen (New York University)

Mandana Modirrousta (University of Manitoba)

David Perez (Harvard University)

Rani Sarkis (Harvard University)

Robert Shura (Salisbury VAMC)

Ottavio Vittolo (Harvard University, Remalda Therapeutics Inc)

Valerie Voon (University of Cambridge)


Publications

1.      Pressman PS, Matlock D, Ducharme S. Distinguishing Behavioral Variant Frontotemporal Dementia From Primary Psychiatric Disorders: A Review of Recently Published Consensus Recommendations From the Neuropsychiatric International Consortium for Frontotemporal Dementia. J Neuropsychiatry Clin Neurosci. 2021 Jan 14:appineuropsych20090238. doi: 10.1176/appi.neuropsych.20090238. Epub 2021 Jan 14.

2.      Perez DL, Aybek S, Popkirov S, Kozlowska K, Stephen CD, Anderson J, Shura R, Ducharme S, Carson A, Hallett M, Nicholson TR, Stone J, LaFrance WC Jr, Voon V; (On behalf of the American Neuropsychiatric Association Committee for Research). A Review and Expert Opinion on the Neuropsychiatric Assessment of Motor Functional Neurological Disorders. J Neuropsychiatry Clin Neurosci. 2021 Winter;33(1):14-26. doi: 10.1176/appi.neuropsych.19120357. Epub 2020 Aug 11.

3.      Baslet G, Bajestan SN, Aybek S, Modirrousta M, D Clin Psy JP, Cavanna A, Perez DL, Lazarow SS, Raynor G, Voon V, Ducharme S, LaFrance WC Jr. Evidence-Based Practice for the Clinical Assessment of Psychogenic Nonepileptic Seizures: A Report From the American Neuropsychiatric Association Committee on Research. J Neuropsychiatry Clin Neurosci. 2021 Winter;33(1):27-42. doi: 10.1176/appi.neuropsych.19120354. Epub 2020 Aug 11.

  1. Sarkis RA, Coffey MJ, Cooper JJ, Hassan I, Lennox B. Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Review of Psychiatric Phenotypes and Management Considerations: A Report of the American Neuropsychiatric Association Committee on Research. J Neuropsychiatry Clin Neurosci. 2019;31(2):137-142.
  2. Victoroff J, Lin FV, Coburn KL, Shillcutt SD, Voon V, Ducharme S. Noncognitive Behavioral Changes Associated With Alzheimer's Disease: Implications of Neuroimaging Findings.J Neuropsychiatry Clin Neurosci. 2018;30(1):14-21.
  3. Cavanna AE, Black KJ, Hallett M, Voon V. Neurobiology of the Premonitory Urge in Tourette's Syndrome: Pathophysiology and Treatment Implications. J Neuropsychiatry Clin Neurosci. 2017;29(2):95-104.
  4. Ducharme S, Bajestan S, Dickerson BC, Voon V. Psychiatric Presentations of C9orf72 Mutation: What Are the Diagnostic Implications for Clinicians? J Neuropsychiatry Clin Neurosci. 2017;29(3):195-205.
  5. Voon V, Cavanna AE, Coburn K, Sampson S, Reeve A, LaFrance WC Jr; (On behalf of the American Neuropsychiatric Association Committee for Research). Functional Neuroanatomy and Neurophysiology of Functional Neurological Disorders (Conversion Disorder). J Neuropsychiatry Clin Neurosci. 2016;28(3):168-90.
  6. Victoroff J, Coburn K, Reeve A, Sampson S, Shillcutt S. Pharmacological management of persistent hostility and aggression in persons with schizophrenia spectrum disorders: a systematic review. J Neuropsychiatry Clin Neurosci. 2014;26(4):283-312.
  7. Lauterbach EC, Mendez MF: Psychopharmacological Neuroprotection In Neurodegenerative Diseases, Part III: Criteria-Based Assessment: A Report Of The ANPA Committee On Research. Journal of Neuropsychiatry and Clinical Neurosciences 2011;23(3):242-60.
  8. Lauterbach EC, Victoroff J, Coburn KL, Shillcutt SD, Doonan SM, Mendez MF. Psychopharmacological Neuroprotection In Neurodegenerative Disease: Assessing The Preclinical Data. Journal of Neuropsychiatry and Clinical Neurosciences 2010;22(1):8-18.
  9. Lauterbach EC, Shillcutt SD, Victoroff J, Coburn KL, Mendez MF. Psychopharmacologic- al Neuroprotection In Neurodegenerative Disease: Heuristic Clinical Applications. Journal of Neuropsychiatry and Clinical Neurosciences 2010;22(2):130-54.
  10. Parvizi J, Coburn KL, Shillcutt SD, Coffey CE, Lauterbach EC, Mendez F. Neuroanatomy Of Pathological Laughing And Crying: A Report Of The American Neuropsychiatric Association Committee On Research. Journal of Neuropsychiatry and Clinical Neurosciences 2009;21(1):75-87.
  11. Mendez MF, Lauterbach EC, Sampson S. An Evidence Based Review Of The Psycho- pathology Of Frontotemporal Dementia And Related Syndromes, Journal of Neuropsychiatry and Clinical Neurosciences 2008;20(2):130-149.
  12. Kim E, Lauterbach EC, Reeve A, Arciniegas DB, Coburn KL, Mendez MF, Rummans TA, Coffey CE. Neuropsychiatric Complications Of Traumatic Brain Injury: A Critical Review Of The Literature. Journal of Neuropsychiatry and Clinical Neurosciences 2007;19(2):106-27.
  13. Royall DR, Lauterbach EC, Kaufer DI, Malloy P, Coburn KL, Black KJ; Committee on Research of the American Neuropsychiatric Association. The Cognitive Correlates of Functional Status. Journal of Neuropsychiatry and Clinical Neurosciences 2007;19(3):249-65.
  14. Coburn KL, Lauterbach EC, Boutros NN, Black K, Arciniegas DB, Coffey CE. The Value Of Quantitative Electroencephalography In Clinical Psychiatry: a report by the Committee on Research of the American Neuropsychiatric Association. Journal of Neuro- psychiatry and Clinical Neurosciences 2006;18(4):460-500.
  15. Royall DR, Lauterbach EC, Cummings JL, Reeve A, Rummans TA, Kaufer DI, LaFrance WC, Coffey CE, et al. Executive control function. A review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. Journal of Neuropsychiatry and Clinical Neurosciences 2002;14(4):377-405.
  16. LaFrance WC, Lauterbach EC, Coffey CE, Salloway SP, Kaufer DI, Reeve A, Royall DR, Aylward E, Rummans TA, Lovell MR. The use of herbal alternative medicines in neuropsychiatry. A report of the ANPA Committee on Research. Journal of Neuropsychiatry and Clinical Neurosciences 2000;12(2):177-192.
  17. Rummans TA, Lauterbach EC, Coffey CE, Royall DR, Cummings JL, Salloway SP, Duffy J, Kaufer D. Pharmacologic efficacy in neuropsychiatry: a review of placebo - controlled treatment trials. Journal of Neuropsychiatry and Clinical Neurosciences 1999;11(2):176-189
  18. Lauterbach EC, Cummings JL, Duffy J, Coffey CE, Kaufer D, Mark Lovell, Malloy P, Reeve A, Royall DR, Rummans TA, Salloway SP. Neuropsychiatric correlates and treatment of lenticulostriatal diseases: a review of the literature and overview of research opportunities in Huntington’s, Wilson’s, and Fahr’s diseases. Journal of Neuropsychiatry and Clinical Neurosciences Neurosci 1998;10(3):249-266.
  19. Cummings JL, Coffey CE, Lauterbach EC, Lovell M, Malloy PF, Royall DR, Rummans TA, Salloway S. The Clinican-Scientist in Neuropsychiatry: A Position Statement From the Committee on Research of the American Neuropsychiatric Association. Journal of Neuropsychiatry and Clinical Neurosciences 1998;10(1):1-9.
  20. Malloy PF, Cummings JL, Coffey CE, Duffy J, Fink EC, Lauterbach EC, Lovell M, Royall D, Salloway S. Cognitive screening instruments in neuropsychiatry: a report of the Committee on Research of the American Neuropsychiatric Association. Journal of Neuropsychiatry and Clinical Neurosciences 1997;9(2):189-197.
  21. Coffey CE, Cummings JL, Duffy J, Fink M, Lauterbach EC, Lovell M, et al. Assessment of Treatment Outcomes In Neuropsychiatry. A Report From The Committee On Research Of The American Neuropsychiatric Association. Journal of Neuropsychiatry and Clinical Neuroscience 1995;7(3):287-289.

Past ANPA CoR Chairs

Valerie Voon 2013-2019

Shirlene Sampson 2011-2013

Mario Mendez 2007-2011

Ed Lauterbach 1999-2007

Jim Duffy 1997-1999

Ed Coffey 1993-1997


WHAT IS NEUROPSYCHIATRY?

A scientific field

When used to refer to a scientific field, neuropsychiatry is the integrated study of psychiatric and neurologic disorders. This definition of neuropsychiatry does not connote a particular type of educational background or professional training; instead, it refers broadly and inclusively of the work performed any basic or clinical scientist, educator, clinician, public policy maker, or other individual that seeks to advance our understanding of the neurological bases of psychiatric disorders, the psychiatric manifestations of neurological disorders, and/or the evaluation and care of persons with neurologically based behavioral disturbances. In other words, one’s work can be neuropsychiatric regardless of whether one is trained as a neuropsychiatrist.

A medical subspecialty

When used to refer to a medical subspecialty, neuropsychiatry is one of the two historically separate but parallel clinical disciplines that comprise the medical subspecialty known currently as Behavioral Neurology & Neuropsychiatry. While the knowledge base and clinical skills of behavioral neurologists and neuropsychiatrists are built upon on the foundation established by primary training in one or both of these specialties, expertise and clinical competence in Behavioral Neurology & Neuropsychiatry requires experience specific to the evaluation, differential diagnosis, prognosis, pharmacological treatment, psychosocial management, and neurorehabilitation of persons with complex neuropsychiatric and neurobehavioral conditions.


TERMS OF USE  PRIVACY

© 2016 American Neuropsychiatric Association (ANPA). All rights reserved.

PO Box 97 Abilene, KS 67410-1707. anpaoffice@gmail.com